If the initiative proceeds as planned, it will mark a pivotal shift in the regulatory landscape, introducing both efficiencies and novel ...

AI adoption in the corporate world is not a sprint—it’s a strategic journey where early experimentation gives way to ...

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

Lantern Pharma's Q1 2025 earnings reveal clinical progress, AI commercialization plans, and financial discipline.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

We recently published a list of the 10 Most Popular AI Stocks to Avoid Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

GE HealthCare (Nasdaq: GEHC) today announced the launch of its CleaRecon DL technology for enhancing CBCT imaging.

Tech companies are focusing on AI products over research, say industry experts, who are sounding the alarm about safety.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

FDA seeking 'aggressive' adoption of AI . The FDA announced an "aggressive timeline" to deploy artificial intelligence ...